Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5000
-0.0023 (-0.46%)
At close: Jun 18, 2026, 4:00 PM EDT
0.5150
+0.0150 (3.00%)
After-hours: Jun 18, 2026, 4:26 PM EDT
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
16.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKTTA News
- 2 days ago - Pasithea Therapeutics announces amendments to PAS-004 clinical study - TheFly
- 2 days ago - Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial - GlobeNewsWire
- 3 days ago - Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - GlobeNewsWire
- 16 days ago - Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA - TheFly
- 16 days ago - Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 20 days ago - Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis - TheFly
- 6 weeks ago - Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer - TheFly
- 6 weeks ago - Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire